| http://dbpedia.org/ontology/abstract
|
Il dronedarone (INN) è un farmaco anti-ari … Il dronedarone (INN) è un farmaco anti-aritmico utilizzato principalmente nelle recidive di fibrillazione atriale e di flutter atriale. È commercializzato in U.S.A e in Europa con il nome di Multaq. È stato approvato dalla Food and Drug Administration nel luglio del 2009 ed è stato utilizzato principalmente in alternativa all'amiodarone in soggetti rientrati in ritmo sinusale o che si dovevano sottoporre a cardioversione farmacologica o elettrica del ritmo. Non essendo emersa, nei diversi studi clinici, una riduzione significativa della mortalità nei pazienti trattati, per contro associata a un aumento della stessa nei pazienti con insufficienza cardiaca da moderata a grave (classe NYHA III-IV), l'FDA ne ha controindicato l'utilizzo nell'insufficienza cardiaca, estendendone la limitazione anche ai pazienti con recente episodio di scompenso cardiaco, che hanno necessitato di ricovero ospedaliero.hanno necessitato di ricovero ospedaliero.
, Dronedarona (Multaq®) es un fármaco antiar … Dronedarona (Multaq®) es un fármaco antiarrítmico para el tratamiento de los trastornos del ritmo cardíaco. Gracias a los resultados del estudio ATHENA, en julio de 2009 dronedarona ha sido aprobada por la Food and Drug Administration (FDA) estadounidense para el tratamiento de la fibrilación auricular y el flúter auricular. Dronedarona es el primer antiarrítmico autorizado con efectos clínicos beneficiosos de reducción de las hospitalizaciones por causa cardiovascular en pacientes con fibrilación auricular (paroxística o intermitente) o flúter auricular. El lanzamiento comercial está previsto para el verano de 2009. En Europa, hay un expediente de registro en fase de revisión administrativa por parte de la Agencia Europea de Medicamentos (EMEA).la Agencia Europea de Medicamentos (EMEA).
, Dronedaron (Handelsname Multaq) ist der Fr … Dronedaron (Handelsname Multaq) ist der Freiname eines Arzneistoffes, der als Antiarrhythmikum zur Behandlung von Herzrhythmusstörungen eingesetzt wird. Das Medikament wird als 400-mg-Tabletten von Sanofi produziert und vermarktet. Die empfohlene Dosierung ist eine zweimal tägliche Einnahme von 400 mg.eine zweimal tägliche Einnahme von 400 mg.
, 드로네다론(Dronedarone, 개발코드명 SR33589)은 항부정맥제다. 프랑스 사노피 어벤티스사가 멀택(Multaq)이란 상표명으로 시판중이다.
, درونيدارون (بالإنجليزية: Dronedarone) ، هو دواء من شركة سانوفي، يستخدم لعلاج عدم انتظام ضربات القلب، الرجفان الأذيني والرفرفة الأذينية أو الذين خضعوا للعلاج الدوائي أو العلاج بالصدمة الكهربائية.
, Dronedarone, sold under the brand name Mul … Dronedarone, sold under the brand name Multaq, is a medication by Sanofi-Aventis, mainly for the indication of cardiac arrhythmias. It was approved by the FDA on July 2, 2009. It was recommended as an alternative to amiodarone for the treatment of atrial fibrillation and atrial flutter in people whose hearts have either returned to normal rhythm or who undergo drug therapy or electric shock treatment i.e. direct current cardioversion (DCCV) to maintain normal rhythm. It is a class III antiarrhythmic drug. In the United States, the FDA approved label includes a claim for reducing hospitalization, but not for reducing mortality, as a reduction in mortality was not demonstrated in the clinical development program. A trial of the drug in heart failure was stopped as an interim analysis showed a possible increase in heart failure deaths, in patients with moderate to severe CHF. The U.S. label for dronedarone includes a boxed warning, stating that dronedarone is contraindicated in patients with NYHA Class IV heart failure, with NYHA Class II–III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic, or with permanent atrial fibrillation." Dronedarone is also associated with rare cases of severe liver damage, including liver failure.ere liver damage, including liver failure.
, Le dronédarone est un médicament antiarythmique administrable par voie orale et utilisé dans le traitement de la fibrillation auriculaire pour diminuer le risque de récidive.
, Дронедарон — синтетичний антиаритмічний препарат ІІІ класу для перорального застосування. Дронедарон розроблений компанією «Sanofi-Aventis», та випускається нею під торговою назвою «Мультак».
|
| http://dbpedia.org/ontology/alternativeName
|
Multaq
|
| http://dbpedia.org/ontology/bioavailability
|
15
|
| http://dbpedia.org/ontology/casNumber
|
141626-36-0
|
| http://dbpedia.org/ontology/chEBI
|
50659
|
| http://dbpedia.org/ontology/chEMBL
|
184412
|
| http://dbpedia.org/ontology/drugbank
|
DB04855
|
| http://dbpedia.org/ontology/fdaUniiCode
|
JQZ1L091Y2
|
| http://dbpedia.org/ontology/kegg
|
D03914
, D02537
|
| http://dbpedia.org/ontology/medlinePlus
|
a609034
|
| http://dbpedia.org/ontology/pubchem
|
208898
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Dronedarone_structure.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/dronedarone +
, https://druginfo.nlm.nih.gov/drugportal/name/dronedarone%20hydrochloride +
|
| http://dbpedia.org/ontology/wikiPageID
|
7778362
|
| http://dbpedia.org/ontology/wikiPageLength
|
20307
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1106213732
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Bradycardia +
, http://dbpedia.org/resource/Liver +
, http://dbpedia.org/resource/Pulmonary_fibrosis +
, http://dbpedia.org/resource/Category:Phenol_ethers +
, http://dbpedia.org/resource/Defibrillation +
, http://dbpedia.org/resource/Class_III_antiarrhythmic +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/Boxed_warning +
, http://dbpedia.org/resource/Inpatient_care +
, http://dbpedia.org/resource/CYP3A +
, http://dbpedia.org/resource/QT-interval +
, http://dbpedia.org/resource/Iodine +
, http://dbpedia.org/resource/Atrial_fibrillation +
, http://dbpedia.org/resource/Cardiac_arrhythmia +
, http://dbpedia.org/resource/Thyroid +
, http://dbpedia.org/resource/Category:Diarylketones +
, http://dbpedia.org/resource/Category:Antiarrhythmic_agents +
, http://dbpedia.org/resource/Health_Canada +
, http://dbpedia.org/resource/Category:Anilines +
, http://dbpedia.org/resource/Medication +
, http://dbpedia.org/resource/Benzofuran +
, http://dbpedia.org/resource/Category:Sulfonamides +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Hepatic +
, http://dbpedia.org/resource/NYHA_classification +
, http://dbpedia.org/resource/Randomized +
, http://dbpedia.org/resource/Sanofi-Aventis +
, http://dbpedia.org/resource/Mortality_rate +
, http://dbpedia.org/resource/Amiodarone +
, http://dbpedia.org/resource/Sinus_rhythm +
, http://dbpedia.org/resource/Heart_failure +
, http://dbpedia.org/resource/Torsades +
, http://dbpedia.org/resource/Pacemaker +
, http://dbpedia.org/resource/Atrial_flutter +
, http://dbpedia.org/resource/Cardioversion +
, http://dbpedia.org/resource/Antiarrhythmic_agent +
|
| http://dbpedia.org/property/atcPrefix
|
1.0
|
| http://dbpedia.org/property/atcSuffix
|
BD07
|
| http://dbpedia.org/property/bioavailability
|
15.0
|
| http://dbpedia.org/property/c
|
31
|
| http://dbpedia.org/property/casNumber
|
141626
|
| http://dbpedia.org/property/chebi
|
50659
|
| http://dbpedia.org/property/chembl
|
184412
|
| http://dbpedia.org/property/chemspiderid
|
180996
|
| http://dbpedia.org/property/dailymedid
|
Dronedarone
|
| http://dbpedia.org/property/drugbank
|
DB04855
|
| http://dbpedia.org/property/eliminationHalfLife
|
-68400.0
|
| http://dbpedia.org/property/excretion
|
Feces , urine
|
| http://dbpedia.org/property/h
|
44
|
| http://dbpedia.org/property/index2Label
|
as HCl
|
| http://dbpedia.org/property/iupacName
|
N-methanesulfonamide
|
| http://dbpedia.org/property/iupharLigand
|
7465
|
| http://dbpedia.org/property/kegg
|
D02537
, D03914
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalUk
|
POM
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/licenceEu
|
yes
|
| http://dbpedia.org/property/medlineplus
|
a609034
|
| http://dbpedia.org/property/metabolism
|
Extensive Liver
|
| http://dbpedia.org/property/n
|
2
|
| http://dbpedia.org/property/o
|
5
|
| http://dbpedia.org/property/pregnancyAu
|
D
|
| http://dbpedia.org/property/pregnancyUs
|
X
|
| http://dbpedia.org/property/proteinBound
|
>98%
|
| http://dbpedia.org/property/pubchem
|
208898
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/s
|
1
|
| http://dbpedia.org/property/smiles
|
O=SC
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
|
| http://dbpedia.org/property/synonyms
|
SR33589
|
| http://dbpedia.org/property/tradename
|
Multaq
|
| http://dbpedia.org/property/unii
|
JQZ1L091Y2
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
461091509
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Keggcite +
, http://dbpedia.org/resource/Template:Stdinchicite +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Citation_needed +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Ebicite +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Antiarrhythmic_agents +
, http://dbpedia.org/resource/Template:Short_description +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Anilines +
, http://dbpedia.org/resource/Category:Diarylketones +
, http://dbpedia.org/resource/Category:Antiarrhythmic_agents +
, http://dbpedia.org/resource/Category:Sulfonamides +
, http://dbpedia.org/resource/Category:Phenol_ethers +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Drug +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Dronedarone?oldid=1106213732&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Dronedarone_structure.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Dronedarone +
|
| owl:sameAs |
http://fa.dbpedia.org/resource/%D8%AF%D8%B1%D9%88%D9%86%D8%AF%D8%A7%D8%B1%D9%88%D9%86 +
, http://es.dbpedia.org/resource/Dronedarona +
, http://ar.dbpedia.org/resource/%D8%AF%D8%B1%D9%88%D9%86%D9%8A%D8%AF%D8%A7%D8%B1%D9%88%D9%86 +
, http://dbpedia.org/resource/Dronedarone +
, http://sr.dbpedia.org/resource/Dronedaron +
, http://tr.dbpedia.org/resource/Dronedaron +
, http://it.dbpedia.org/resource/Dronedarone +
, http://uk.dbpedia.org/resource/%D0%94%D1%80%D0%BE%D0%BD%D0%B5%D0%B4%D0%B0%D1%80%D0%BE%D0%BD +
, http://yago-knowledge.org/resource/Dronedarone +
, http://ko.dbpedia.org/resource/%EB%93%9C%EB%A1%9C%EB%84%A4%EB%8B%A4%EB%A1%A0 +
, http://de.dbpedia.org/resource/Dronedaron +
, http://sh.dbpedia.org/resource/Dronedaron +
, http://www.wikidata.org/entity/Q408637 +
, http://fr.dbpedia.org/resource/Dron%C3%A9darone +
, http://rdf.freebase.com/ns/m.01xm8sc +
, https://global.dbpedia.org/id/3nELB +
|
| rdf:type |
http://dbpedia.org/class/yago/Abstraction100002137 +
, http://www.wikidata.org/entity/Q8386 +
, http://umbel.org/umbel/rc/DrugProduct +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/WikicatKetones +
, http://dbpedia.org/class/yago/Quintessence114847103 +
, http://dbpedia.org/class/yago/Element114840755 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Amine114739004 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/MethaneSeries114951377 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/WikicatAmines +
, http://dbpedia.org/class/yago/WikicatAromaticKetones +
, http://dbpedia.org/class/yago/Ketone114926294 +
, http://dbpedia.org/class/yago/WikicatBenzofurans +
, http://dbpedia.org/class/yago/Benzofuran114898101 +
, http://dbpedia.org/class/yago/AliphaticCompound114601294 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/WikicatPhenolEthers +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/Part113809207 +
|
| rdfs:comment |
Il dronedarone (INN) è un farmaco anti-ari … Il dronedarone (INN) è un farmaco anti-aritmico utilizzato principalmente nelle recidive di fibrillazione atriale e di flutter atriale. È commercializzato in U.S.A e in Europa con il nome di Multaq. È stato approvato dalla Food and Drug Administration nel luglio del 2009 ed è stato utilizzato principalmente in alternativa all'amiodarone in soggetti rientrati in ritmo sinusale o che si dovevano sottoporre a cardioversione farmacologica o elettrica del ritmo. Non essendo emersa, nei diversi studi clinici, una riduzione significativa della mortalità nei pazienti trattati, per contro associata a un aumento della stessa nei pazienti con insufficienza cardiaca da moderata a grave (classe NYHA III-IV), l'FDA ne ha controindicato l'utilizzo nell'insufficienza cardiaca, estendendone la limitazione nza cardiaca, estendendone la limitazione
, Le dronédarone est un médicament antiarythmique administrable par voie orale et utilisé dans le traitement de la fibrillation auriculaire pour diminuer le risque de récidive.
, 드로네다론(Dronedarone, 개발코드명 SR33589)은 항부정맥제다. 프랑스 사노피 어벤티스사가 멀택(Multaq)이란 상표명으로 시판중이다.
, Dronedarona (Multaq®) es un fármaco antiar … Dronedarona (Multaq®) es un fármaco antiarrítmico para el tratamiento de los trastornos del ritmo cardíaco. Gracias a los resultados del estudio ATHENA, en julio de 2009 dronedarona ha sido aprobada por la Food and Drug Administration (FDA) estadounidense para el tratamiento de la fibrilación auricular y el flúter auricular. Dronedarona es el primer antiarrítmico autorizado con efectos clínicos beneficiosos de reducción de las hospitalizaciones por causa cardiovascular en pacientes con fibrilación auricular (paroxística o intermitente) o flúter auricular. El lanzamiento comercial está previsto para el verano de 2009. En Europa, hay un expediente de registro en fase de revisión administrativa por parte de la Agencia Europea de Medicamentos (EMEA).la Agencia Europea de Medicamentos (EMEA).
, Dronedarone, sold under the brand name Mul … Dronedarone, sold under the brand name Multaq, is a medication by Sanofi-Aventis, mainly for the indication of cardiac arrhythmias. It was approved by the FDA on July 2, 2009. It was recommended as an alternative to amiodarone for the treatment of atrial fibrillation and atrial flutter in people whose hearts have either returned to normal rhythm or who undergo drug therapy or electric shock treatment i.e. direct current cardioversion (DCCV) to maintain normal rhythm. It is a class III antiarrhythmic drug. In the United States, the FDA approved label includes a claim for reducing hospitalization, but not for reducing mortality, as a reduction in mortality was not demonstrated in the clinical development program. A trial of the drug in heart failure was stopped as an interim analysis showed was stopped as an interim analysis showed
, Дронедарон — синтетичний антиаритмічний препарат ІІІ класу для перорального застосування. Дронедарон розроблений компанією «Sanofi-Aventis», та випускається нею під торговою назвою «Мультак».
, Dronedaron (Handelsname Multaq) ist der Fr … Dronedaron (Handelsname Multaq) ist der Freiname eines Arzneistoffes, der als Antiarrhythmikum zur Behandlung von Herzrhythmusstörungen eingesetzt wird. Das Medikament wird als 400-mg-Tabletten von Sanofi produziert und vermarktet. Die empfohlene Dosierung ist eine zweimal tägliche Einnahme von 400 mg.eine zweimal tägliche Einnahme von 400 mg.
, درونيدارون (بالإنجليزية: Dronedarone) ، هو دواء من شركة سانوفي، يستخدم لعلاج عدم انتظام ضربات القلب، الرجفان الأذيني والرفرفة الأذينية أو الذين خضعوا للعلاج الدوائي أو العلاج بالصدمة الكهربائية.
|
| rdfs:label |
Dronédarone
, Дронедарон
, درونيدارون
, Dronedarona
, Dronedaron
, Dronedarone
, 드로네다론
|
